Main Article Content
We conducted a study to evaluate the factor that might associate with survival of the elderly patients diagnosed with advanced Non-Small Cell Lung Cancer disease. A retrospective cohort of 78 patients with age of more than 70 years in Saraburi Hospital were enrolled between July 2010 and December 2014. The median age of the patients was 76 years. It was found that the Eastern Co-operation Oncology Group (ECOG) performance status was the significant factor associated with survival of the elderly patients with Hazard ratio 5.16 (p-value < 0.05, 95% CI 2.82-9.45). One, two and five years of survival were 21.79%, 6.41% and 2.56%, respectively. There was significant difference of median survival time between the elderly patients with and without receiving chemotherapy (10.8 and 1.5 months, p < 0.05). The Grade III-IV adverse effects of the elderly patients receiving chemotherapy were 13% (pneumonia and febrile neutropenia) but no treatment related death was found in this study. In conclusion, the ECOG performance status is the good prognostic factor for the overall survival in the elderly patients diagnosed with advanced Non-Small Cell Lung Cancer. It is a good guide for physician to treat the elderly patients with chemotherapy properly.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
2. Mäkitaro R, Pääkko P, Huhti E, Bloigu R, Kinnula VL. Prospective population-based study on the survival of patients with lung cancer. Eur Respir J 2002; 19(6): 1087-92.
3. Bryant A, Cerfolio RJ. Diff erences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest 2007; 132(1): 185-92.
4. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Smoking and lung cancer survival: the role of comorbidity and treatment. Chest 2004; 125(1): 27-37.
5. Ito Y, Ohno Y, Rachet B, Coleman MP, Tsukuma H, Oshima A. Cancer survival trends in Osaka, Japan: the infl uence of age and stage at diagnosis. Jpn J Clin Oncol 2007; 37(6): 452-8.
6. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346(2): 92-8.
7. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and fi nal overall survival results from a phase III, randomized, open-label, fi rst-line study of gefi tinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29(21): 2866-74.
8. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361(10): 947-57.
9. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5(6): 649-55.
10. Tam TC, Ho JC, Wong MK, Wong WM, Wang JK, Lam JC, et al. Treatment outcomes in elderly with advanced-stage non-small cell lung cancer. Lung 2013; 191(6): 645-54.
11. Booton R, Jones M, Thatcher N. Lung cancer 7: management of lung cancer in elderly patients. Thorax 2003; 58(8): 711-20.
12. Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, et al. Chemotherapy forelderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95(5): 362-72.